Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Operating Leases (2021 - 2026)

Pliant Therapeutics has reported Operating Leases over the past 6 years, most recently at $28.8 million for Q1 2026.

  • Quarterly Operating Leases fell 3.7% to $28.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $28.8 million through Mar 2026, down 3.7% year-over-year, with the annual reading at $27.7 million for FY2025, 6.05% down from the prior year.
  • Operating Leases was $28.8 million for Q1 2026 at Pliant Therapeutics, up from $27.7 million in the prior quarter.
  • Over five years, Operating Leases peaked at $29.9 million in Q1 2025 and troughed at $2.3 million in Q2 2023.
  • The 5-year median for Operating Leases is $23.7 million (2024), against an average of $17.2 million.
  • Year-over-year, Operating Leases plummeted 58.81% in 2023 and then soared 731.58% in 2024.
  • A 5-year view of Operating Leases shows it stood at $3.4 million in 2022, then tumbled by 32.4% to $2.3 million in 2023, then surged by 1170.02% to $29.4 million in 2024, then fell by 6.05% to $27.7 million in 2025, then increased by 4.07% to $28.8 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Operating Leases are $28.8 million (Q1 2026), $27.7 million (Q4 2025), and $29.4 million (Q3 2025).